查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2103680

止吐藥市場：全球市場預測，2026-2032年

Antiemetic Drugs Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，止吐藥市場規模將達到 132.1 億美元，複合年成長率為 6.12%。

主要市場統計數據
基準年 2025 87.1億美元
預計年份：2026年 92.2億美元
預測年份 2032 132.1億美元
複合年成長率 (%) 6.12%

止吐藥執行摘要

止吐藥是預防和治療化療、放射線治療、懷孕、胃腸炎、偏頭痛、暈動病、鴉片類藥物使用以及其他胃腸道和前庭疾病相關噁心和嘔吐的重要治療方法。此類藥物包括5-羥色胺3（5-HT3）受體拮抗劑、神經激肽-1（N1）受體拮抗劑、多巴胺拮抗劑、抗組織胺、抗膽鹼能藥物、皮質類固醇、大麻素以及旨在改善症狀控制和提高患者依從性的固定劑量和緩釋製劑。推動止吐藥需求成長的因素包括：全球癌症治療負擔日益加重、外科手術數量增加、門診和日間護理使用率上升，以及臨床上日益重視生活品質、水合狀態、營養狀況和治療連續性。在腫瘤學領域，基於指南的預防性止吐藥物給藥仍然是化療和放射線治療支持治療的關鍵要素，尤其是在癌症治療中，其重要性更加凸顯，因為癌症治療中擴大聯合使用高致吐性化療方案、免疫療法、標靶治療以及複雜的多方面治療方案。在手術全期護理中，止吐策略對於緩解術後噁心嘔吐至關重要，否則可能導致延遲出院和增加計劃外臨床干預。此外，監管、藥物安全監測、學名藥競爭、製劑創新以及支付方對成本效益處方的壓力等因素也影響著該產業的發展。隨著醫療保健系統優先考慮實證支持治療，止吐藥物已被公認為在醫院、腫瘤科、急診室、產科、小兒科和基層醫療機構中具有重要臨床意義和效用的治療方法。

止吐藥領域的變革性變化

止吐藥領域正經歷著從被動症治療轉變為主動風險分層的。臨床方案擴大根據嘔吐風險、病患病歷、年齡、懷孕狀態、共病、藥物交互作用和先前反應來調整止吐藥的給藥方案，從而提高治療選擇的精準性。腫瘤支持治療正轉向合併預防性治療，包括在某些高風險化療情況下採用基於5-HT3受體拮抗劑、NK1受體拮抗劑、地塞米松和Olanzapine的方案。這反映了控制多個路徑能夠改善急性及遲發性噁心嘔吐預後的證據。同時，日間手術中心和門診腫瘤診所對適用於當日治療模式的口服、經皮、口崩壞和長效止吐藥製劑的需求日益成長。此外，隨著臨床醫生考慮QT間期延長、錐體外系症狀、鎮靜作用、抗膽鹼能作用、妊娠期安全性數據以及老年人群的脆弱性等因素，安全性差異化變得日益重要。另一個重大轉變是價值醫學的日益普及。在這種模式下，減少可避免的急診就診、脫水、治療中斷和術後延誤可直接提升醫療保健系統的績效。專利到期、學名藥的出現、癌症治療的擴展（間接增加了對支持性治療的需求）以及醫院更嚴格的採購制度也都在影響競爭格局。這些變化共同作用，使得臨床證據、劑型便利性、耐受性、供應可靠性以及指引依從性成為止吐藥應用的關鍵因素。

人工智慧對止吐藥物治療的累積影響

人工智慧 (AI) 正開始影響止吐藥物的研發、臨床決策支援、藥物安全監測和治療路徑最佳化。在腫瘤學領域，AI 驅動的風險模型可以分析治療方案、患者人口統計特徵、既往噁心嘔吐史、實驗室檢查結果、共病、伴隨用藥以及真實世界結局，從而識別化療誘發噁心嘔吐高風險患者。這有助於採取更個人化的預防措施和早期療育，尤其適用於報告頻率低於急性嘔吐的遲發性噁心。在手術全期照護中，預測分析可透過整合電子健康記錄類型、鴉片類藥物使用、手術時間、性別、吸菸狀況、暈動病史和先前術後噁心等因素，增強術後噁心嘔吐的風險評估。 AI 還可以透過檢測電子病歷、自發性通報系統和保險理賠資料集中的不利事件模式、藥物交互作用徵兆和仿單標示外用藥趨勢，來支援藥物安全監測。在研發領域，機器學習可以幫助識別受體結合模式、最佳化製劑特性並確定候選組合的優先級，但臨床檢驗和監管批准仍然至關重要。因此，人工智慧的整體影響並非取代臨床醫生的判斷，而是透過改進預防性藥物的選擇、減輕症狀負擔、提高用藥依從性以及產生真實世界證據來加強循證醫學證據。人工智慧的成功應用需要透明的演算法、多樣化的資料集、隱私保護、互通性以及對弱勢群體（例如兒童、孕婦、老年人和接受複雜抗癌治療的患者）的持續偏差監測。

關於止吐藥的關鍵區域性見解

由於癌症診斷和治療能力的提升、手術量巨大、多個經濟體醫療成本不斷上漲，以及抗癌藥物和支持治療方案的可及性提高，亞太地區成為止吐藥的重點發展區域。中國、印度、日本、韓國、澳洲和東協市場的需求模式各不相同。日本、韓國和澳洲市場的健保報銷體系和指引應用較為成熟，而中國、印度和東南亞市場的可近性正迅速擴大。在歐洲，完善的臨床指南、藥物安全監測系統、學名藥的廣泛應用以及結構化的癌症治療和手術全期護理路徑都是優勢；然而，各國醫保報銷體系的差異影響了新型止吐聯合治療和長效製劑的可及性。北美地區則以積極採納癌症支持治療指南、先進的醫院藥房系統、高比例的門診化療以及在外科手術中廣泛應用圍手術全期風險評估為特徵。在美國和加拿大，循證處方、最大限度減少鴉片類藥物使用的手術全期護理路徑以及患者自述症狀管理仍然受到重視。拉丁美洲的特點是癌症治療基礎設施不斷完善，都市區醫療資源取得存在差異，以及公共部門採購優先事項，其中巴西和墨西哥在區域癌症治療和醫院需求方面發揮核心作用。非洲的醫療環境較為分散，止吐藥的可近性取決於基本藥物的供應、癌症治療的擴展、外科醫療服務提供者的能力以及供應鏈的韌性。都市區轉診醫院的需求最高，但在許多地區，經濟負擔和基礎設施差異限制了止吐藥的供應。在中東，尤其是在高所得的海灣市場，透過對三級醫院、癌症中心、醫療旅遊中心的投資以及處方藥清單的現代化，正在取得進展。

北約、七國集團、金磚國家、歐盟、東協和海灣合作理事會的關鍵集團分析

北約成員國與北美和歐洲的重疊區域顯著，其特點通常是：醫院採購系統先進、急診和外科醫療服務完善、藥品品質標準嚴格、藥品供應充足。七國集團（G7）國家普遍高度遵循臨床規範，擁有成熟的癌症治療和手術全期護理路徑以及完善的法律規範體系，在這些國家，證據品質、安全性和真實世界臨床結果在產品定位中尤為重要。金磚國家（BRICS）的癌症治療在中國、印度和巴西取得了顯著進展，加上公共部門的成本控制、對本地生產的偏好以及學名藥。然而，各國的衛生技術評估和報銷流程仍會影響新型止吐方案的採用。東協地區對止吐藥的需求得益於醫院網路的擴張、化療的提高、醫療旅遊的蓬勃發展以及門診服務的擴展，儘管高所得都市區與資源匱乏地區在醫療服務可及性方面存在顯著差異。海灣合作理事會（GCC）成員國在癌症治療中心、先進的外科手術和醫院處方集投入大規模，這為基於指南的止吐和預防性治療以及高品質製劑的推廣創造了有利條件，而醫保報銷機制也促進了這些藥物的普及。全部區域普遍存在的需求是：價格合理、供應穩定、臨床有效的聯合治療以及符合門診癌症治療和日間手術流程的製劑。

主要國家止吐藥趨勢

在中國，隨著癌症診斷的普及、化療的可及性提高以及醫院現代化進程的推進，臨床對止吐藥的需求日益成長。政策重點關注藥品可負擔性和基於數量的採購，也影響這一領域的趨勢。美國是止吐藥使用​​的主要中心，這得益於其廣泛的腫瘤治療、門診手術、急診醫學以及積極採納支持性治療指南。同時，日本得益於其老齡化人口、對臨床方案的高度遵循以及先進的醫院體系，在止吐藥的使用方面，尤其是在腫瘤領域，已相當成熟。印度擁有龐大的患者需求、強大的國內生產能力以及不斷完善的腫瘤基礎設施，但藥品可負擔性和區域醫療保健差異仍然是決定性因素。在德國、英國、法國、義大利和西班牙，癌症治療和手術全期護理中止吐藥的使用方案已較為成熟，國家醫保報銷體系和學名藥的可及性影響著處方行為。德國和法國的醫院藥房對止吐藥的使用進行嚴格管治，而英國強調基於指南的品質和成本效益。在澳大利亞，循證處方和透過系統化的保險報銷制度實現的廣泛可及性是其特徵。在韓國，先進的癌症治療、高科技的應用以及嚴格的保險報銷審查共同支持了成熟和新型止吐療法的系統性應用。在加拿大，標準化診療路徑、處方藥清單的評估以及各省醫療保健系統間的公平可及性備受重視。在俄羅斯，需求取決於癌症和外科治療能力，而供應鏈的複雜性和法規的在地化程度則影響藥物的可及性。巴西是拉丁美洲止吐藥需求中心，這得益於其大規模的癌症治療和醫院網路，但藥物的可及性和價格承受能力影響著患者的選擇。在墨西哥，隨著癌症治療和醫院服務的擴展，止吐藥需求不斷成長，但公立和私立醫療保健系統之間可近性的差異仍然是一個重大挑戰。

為行業領導者提供的實用建議

行業領導者應優先考慮產生符合指南的證據。這些證據必須證明能顯著減少噁心嘔吐、急救藥物的使用、脫水相關干預措施、治療中斷以及經皮延遲出院。產品策略應著重於耐受性、給藥便利性、對延遲症狀的持續療效以及患者友善的製劑，例如口崩壞、透皮貼片和長效製劑，從而使其區別於競爭對手的產品。製藥公司和經銷商應加強基本止吐藥的供應穩定性，因為供不應求會直接擾亂化療和手術全期方案。市場進入團隊應根據支付方的期望調整證據材料，強調真實世界結果、藥物經濟學價值以及與腫瘤和外科治療路徑的契合度。臨床教育應關注噁心這一未被充分認知的負擔、預防性治療中合理的聯合用藥、安全性考慮因素以及特定患者群體（例如兒童、孕婦、老年人和心血管風險患者）的需求。整合數位健康技術，包括症狀追蹤和人工智慧驅動的風險分層，可以改善及時干預並產生上市後證據。此外，企業應推行區域策略，尤其是在新興市場關注藥品的可負擔性和可近性，在成熟市場關注劑型和安全性差異化，以及在採購主導系統中與醫院處方藥清單保持一致。最重要的是，競爭優勢在於將臨床可靠性、法規遵從性、以患者為中心的設計以及強大的生產能力與對改善支持性護理結果的明確承諾相結合。

調查方法

本執行摘要基於對檢驗的二手資料和公認的臨床研究結果的系統性回顧，內容涵蓋止吐藥的藥理學、腫瘤支持治療、手術全期噁心嘔吐的管理、監管標準以及區域醫療保健系統趨勢。調查方法包括對來自臨床指南、同行評審文獻、藥物附加檔和安全資訊、公共衛生資料集、醫療保健利用指標、國家和地區政策文件以及藥物警戒資源的證據進行三角驗證。檢驗重點在於定性行業趨勢、治療使用模式、監管和報銷考慮、技術影響以及區域准入因素。為維持與實證策略解讀的一致性，而非進行推測性量化，本摘要刻意排除了市場規模估算、佔有率分析和預測。透過比較醫療保健基礎設施成熟度、腫瘤和外科採購慣例、報銷環境以及准入限制，得出區域、群體和國家層面的具體見解。人工智慧的影響分析透過風險預測、臨床決策支援、真實世界數據（REW）產生、藥物發現和安全性監測等成熟應用進行評估，重點在於檢驗、透明度、互通性和偏差監測等實施要求。所有研究結果均被整合，旨在為製藥、醫療保健和生命科學領域的相關人員提供決策支持，幫助他們更清晰地了解止吐藥的現狀。

結論

止吐藥物仍然是現代支持治療的重要組成部分，它能幫助患者繼續接受癌症治療，術後更有效地康復，避免可預防的併發症，並維持營養、水分和生活品質。該行業正從廣泛的症狀管理轉向個體化預防、循證聯合治療、以安全性為中心的差異化以及適合門診治療的劑型。不同地區的趨勢差異顯著，成熟市場優先考慮指南遵循和基於價值的治療結果，而新興市場則優先考慮可及性、可負擔性、不斷擴大的基礎設施和供應的持續性。人工智慧 (AI) 透過改進風險預測、真實世界數據 (RWE) 生成、藥物安全監測和病患監測，帶來了新的機遇，前提是其應用經過臨床檢驗並符合倫理規範。對於行業領導者而言，最大的機會在於開發能夠解決遲發性噁心、提高用藥依從性、減少治療中斷以及實現腫瘤科、外科、急診醫學和基層醫療保健路徑無縫銜接的療法和策略。永續的成功需要在創新與可負擔性、安全性與便利性以及全球策略與本地可近性現實之間取得平衡。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：止吐藥市場：依藥物類別分類

  • 皮質類固醇
  • 多巴胺拮抗劑
  • 神經激肽1受體拮抗劑
  • 血清素5-HT3受體拮抗劑

第8章：止吐藥市場：依適應症分類

  • 化療引起的噁心和嘔吐
  • 術後噁心嘔吐
  • 放射線引起的噁心和嘔吐

第9章：止吐藥市場：依給藥途徑分類

  • 靜脈
  • 口服

第10章 止吐藥市場：依最終用戶分類

  • 診所
  • 居家醫療
  • 醫院

第11章 止吐藥市場：依分子類型分類

  • 小分子藥物
  • 生物製藥
  • 大麻素藥物

第12章 止吐藥市場：依通路分類

  • 離線
  • 線上

第13章 止吐藥市場：按地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第14章 止吐藥市場：依組別分類

  • NATO
  • G7
  • BRICS
  • EU
  • ASEAN
  • GCC

第15章 止吐藥市場：依國家分類

  • 中國
  • 美國
  • 日本
  • 印度
  • 德國
  • 英國
  • 澳洲
  • 法國
  • 韓國
  • 義大利
  • 加拿大
  • 俄羅斯
  • 巴西
  • 墨西哥
  • 西班牙

第16章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Abbott Laboratories
  • Alkem Laboratories Limited
  • Amgen Inc
  • Astellas Pharma Inc
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Baxter International Inc
  • Boehringer Ingelheim International GmbH
  • Cipla Limited
  • Dr Reddys Laboratories Limited
  • Eagle Pharmaceuticals Inc
  • Eisai Co Ltd
  • Eli Lilly and Company
  • F Hoffmann-La Roche Ltd
  • Fresenius Kabi AG
  • Glenmark Pharmaceuticals Limited
  • GSK plc
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson
  • Lupin Limited
  • Merck & Co Inc
  • Novartis AG
  • Pfizer Inc
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Limited
  • Torrent Pharmaceuticals Limited
  • Viatris Inc
  • Zydus Lifesciences Limited
Product Code: MRR-C002B1C996F2

The Antiemetic Drugs Market is projected to grow by USD 13.21 billion at a CAGR of 6.12% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.71 billion
Estimated Year [2026] USD 9.22 billion
Forecast Year [2032] USD 13.21 billion
CAGR (%) 6.12%

Antiemetic Drugs Executive Summary

Antiemetic drugs are essential therapies used to prevent and treat nausea and vomiting associated with chemotherapy, radiation therapy, surgery, pregnancy-related nausea, gastroenteritis, migraine, motion sickness, opioid use, and other gastrointestinal or vestibular disorders. The category spans serotonin 5-HT3 receptor antagonists, neurokinin-1 receptor antagonists, dopamine antagonists, antihistamines, anticholinergics, corticosteroids, cannabinoids, and fixed-dose or extended-release regimens designed to improve symptom control and patient adherence. Demand is supported by the rising global burden of cancer treatment, expanding surgical volumes, greater use of outpatient and ambulatory care, and heightened clinical emphasis on quality of life, hydration status, nutrition, and treatment continuity. In oncology, guideline-based antiemetic prophylaxis remains a critical component of chemotherapy and radiotherapy supportive care, particularly as cancer care increasingly combines highly emetogenic regimens, immunotherapy, targeted agents, and complex multimodal protocols. In perioperative care, antiemetic strategies are central to reducing postoperative nausea and vomiting, which can delay discharge and increase unplanned clinical interventions. The industry is also shaped by regulatory scrutiny, drug safety monitoring, generic competition, formulation innovation, and payer pressure for cost-effective prescribing. As healthcare systems prioritize evidence-based supportive care, antiemetic drugs are positioned as clinically important, high-utility therapies across hospital, oncology, emergency, obstetric, pediatric, and primary care settings.

Transformative Shifts in the Antiemetic Drugs Landscape

The antiemetic drugs landscape is being reshaped by the shift from reactive symptom treatment to proactive, risk-stratified prevention. Clinical protocols increasingly match antiemetic regimens to emetogenic risk, patient history, age, pregnancy status, comorbidities, drug interactions, and prior response, improving the precision of therapy selection. Oncology supportive care has moved toward combination prophylaxis, including 5-HT3 antagonists, NK1 antagonists, dexamethasone, and olanzapine-based approaches for selected high-risk chemotherapy settings, reflecting evidence that multi-pathway control improves outcomes for acute and delayed nausea and vomiting. At the same time, ambulatory surgery centers and outpatient oncology clinics are increasing the need for oral, transdermal, orally disintegrating, and long-acting antiemetic formulations that fit same-day care models. Safety differentiation is also becoming more important as clinicians consider QT prolongation, extrapyramidal symptoms, sedation, anticholinergic effects, pregnancy safety data, and geriatric vulnerability. Another major transformation is the growing role of value-based care, where reducing avoidable emergency visits, dehydration, treatment interruptions, and postoperative delays directly supports health system performance. The competitive environment is also influenced by patent expiries, generics, oncology treatment expansion that indirectly increases supportive care needs, and tighter procurement systems in hospitals. Together, these shifts are making clinical evidence, formulation convenience, tolerability, supply reliability, and guideline alignment decisive factors in antiemetic drug adoption.

Cumulative Impact of Artificial Intelligence on Antiemetic Care

Artificial intelligence is beginning to influence antiemetic drug development, clinical decision support, pharmacovigilance, and care pathway optimization. In oncology, AI-enabled risk models can analyze treatment regimen, patient demographics, prior nausea history, laboratory values, comorbidities, concomitant medications, and real-world outcomes to identify individuals at elevated risk for chemotherapy-induced nausea and vomiting. This can support more tailored prophylaxis and earlier intervention, particularly for delayed nausea, which is often underreported compared with acute vomiting. In perioperative care, predictive analytics can strengthen postoperative nausea and vomiting risk assessment by integrating anesthesia type, opioid exposure, surgical duration, sex, smoking status, motion sickness history, and prior postoperative nausea. AI also supports drug safety surveillance by detecting adverse event patterns, medication interaction signals, and off-label use trends across electronic health records, spontaneous reporting systems, and claims datasets. In research and development, machine learning may help identify receptor-binding patterns, optimize formulation attributes, and prioritize candidate combinations, although clinical validation and regulatory acceptance remain essential. The cumulative impact of AI is therefore not a replacement for clinician judgment but an evidence-enhancing layer that can improve prophylaxis selection, reduce symptom burden, support adherence, and generate real-world evidence. Successful deployment will depend on transparent algorithms, diverse datasets, privacy safeguards, interoperability, and ongoing monitoring for bias in vulnerable populations such as children, pregnant patients, older adults, and people receiving complex oncology regimens.

Key Regional Insights for Antiemetic Drugs

Asia-Pacific is a high-priority region for antiemetic drugs because of expanding cancer diagnosis and treatment capacity, large surgical volumes, rising healthcare expenditure in several economies, and broader access to oncology medicines and supportive care protocols. China, India, Japan, South Korea, Australia, and ASEAN markets show differentiated demand patterns, with mature reimbursement and guideline use in Japan, South Korea, and Australia, and rapid access expansion in China, India, and Southeast Asia. Europe benefits from established clinical guidelines, pharmacovigilance systems, broad use of generics, and structured oncology and perioperative care pathways, while national reimbursement differences influence access to newer antiemetic combinations and long-acting formulations. North America remains characterized by strong oncology supportive care guideline adoption, advanced hospital pharmacy systems, high outpatient chemotherapy utilization, and extensive use of perioperative risk assessment in surgical settings. The United States and Canada continue to emphasize evidence-based prescribing, opioid-sparing perioperative pathways, and patient-reported symptom management. Latin America is shaped by growing cancer care infrastructure, unequal access between urban and rural populations, and public-sector procurement priorities, with Brazil and Mexico playing central roles in regional oncology and hospital demand. Africa presents a fragmented environment, where access to antiemetic drugs is tied to essential medicines availability, cancer treatment expansion, surgical care capacity, and supply chain resilience; demand is strongest in urban referral hospitals but constrained by affordability and infrastructure gaps in many settings. The Middle East is advancing through investments in tertiary hospitals, cancer centers, medical tourism hubs, and formulary modernization, especially in high-income Gulf markets.

Key Group Insights Across NATO, G7, BRICS, EU, ASEAN, and GCC

NATO member countries overlap substantially with North America and Europe and are often characterized by advanced hospital procurement systems, established emergency and surgical services, strong pharmaceutical quality standards, and resilient medicine supply requirements. G7 countries generally show high clinical protocol adherence, established cancer and perioperative care pathways, and mature regulatory oversight, making evidence quality, safety, and real-world outcomes especially important for product positioning. BRICS countries collectively represent a large and diverse demand base, combining major oncology treatment expansion in China, India, and Brazil with public-sector cost containment, local production priorities, and domestic pharmaceutical manufacturing capacity. The European Union reflects a highly regulated environment with strong pharmacovigilance, cross-country clinical guideline influence, and broad generic utilization; however, individual national health technology assessment and reimbursement processes continue to shape uptake of newer antiemetic regimens. ASEAN demand for antiemetic drugs is supported by expanding hospital networks, increasing chemotherapy access, growth in medical tourism, and broader use of outpatient care, though access varies significantly between higher-income urban centers and lower-resource settings. The GCC is distinguished by major investments in oncology centers, advanced surgical care, and hospital formularies, creating favorable conditions for guideline-based antiemetic prophylaxis and premium formulations where reimbursement supports adoption. Across these groups, the most consistent themes are the need for affordable access, reliable supply, clinically validated combinations, and formulations that align with outpatient oncology and same-day surgical workflows.

Key Country Insights for Antiemetic Drugs

China is experiencing strong clinical need as oncology diagnosis, chemotherapy access, and hospital modernization continue to expand, with policy attention on drug affordability and volume-based procurement affecting category dynamics. The United States is a major center for antiemetic drug utilization due to extensive oncology treatment, ambulatory surgery, emergency care, and strong adoption of supportive care guidelines, while Japan has sophisticated antiemetic use, especially in oncology, supported by aging demographics, high clinical protocol adherence, and advanced hospital systems. India combines large patient need, domestic manufacturing strength, and increasing oncology infrastructure, while affordability and regional care disparities remain decisive. Germany, the United Kingdom, France, Italy, and Spain demonstrate mature use of antiemetic protocols in oncology and perioperative care, with national reimbursement systems and generic availability influencing prescribing behavior; Germany and France maintain strong hospital pharmacy governance, while the United Kingdom places emphasis on guideline-driven quality and cost-effectiveness. Australia reflects strong evidence-based prescribing and broad access through structured reimbursement, while South Korea combines advanced cancer care, high technology adoption, and disciplined reimbursement review, supporting structured use of both established and newer antiemetic therapies. Canada emphasizes standardized care pathways, formulary evaluation, and equitable access across provincial systems, while Russia has demand tied to oncology and surgical care capacity, with supply chain complexity and regulatory localization influencing access. Brazil is central to Latin American antiemetic demand, supported by large oncology and hospital networks, with procurement and affordability shaping product selection. Mexico shows growing demand linked to expanding cancer care and hospital services, though public-private access differences remain important.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize guideline-aligned evidence generation that demonstrates meaningful reductions in nausea, vomiting, rescue medication use, dehydration-related interventions, treatment interruptions, and delayed discharge after surgery. Product strategies should focus on differentiated tolerability, convenient dosing, extended coverage for delayed symptoms, and patient-friendly formulations such as orally disintegrating, transdermal, and long-acting options. Manufacturers and distributors should strengthen supply reliability for essential antiemetics, as shortages can directly disrupt chemotherapy and perioperative protocols. Market access teams should tailor evidence packages to payer expectations, emphasizing real-world outcomes, pharmacoeconomic value, and fit within oncology and surgical care pathways. Clinical education should address underrecognized nausea burden, appropriate multi-drug prophylaxis, safety considerations, and special population needs in pediatrics, pregnancy, geriatrics, and patients with cardiac risk. Digital health integration, including symptom tracking and AI-supported risk stratification, can improve timely intervention and generate post-market evidence. Companies should also pursue region-specific strategies: affordability and availability in emerging markets, formulation and safety differentiation in mature markets, and hospital formulary alignment across procurement-driven systems. Above all, competitive advantage will depend on combining clinical credibility, regulatory compliance, patient-centered design, and resilient manufacturing with a clear commitment to measurable improvements in supportive care outcomes.

Research Methodology

This executive summary is built from a structured review of verified secondary sources and accepted clinical knowledge related to antiemetic pharmacology, oncology supportive care, perioperative nausea and vomiting management, regulatory standards, and regional healthcare system dynamics. The methodology includes triangulation of evidence from clinical guidelines, peer-reviewed literature, drug labeling and safety communications, public health datasets, healthcare utilization indicators, national and regional policy documents, and pharmacovigilance resources. The analysis focuses on qualitative industry dynamics, therapeutic use patterns, regulatory and reimbursement considerations, technology influence, and regional access factors. It intentionally excludes market sizing, share analysis, and forecasting to maintain alignment with evidence-based strategic interpretation rather than speculative quantification. Regional, group, and country insights were developed by comparing healthcare infrastructure maturity, oncology and surgical care development, formulary and procurement practices, reimbursement environments, and access constraints. AI impact analysis was assessed through documented applications in risk prediction, clinical decision support, real-world evidence generation, drug discovery, and safety surveillance, with emphasis on implementation requirements such as validation, transparency, interoperability, and bias monitoring. All findings were synthesized to support decision-making for pharmaceutical, healthcare, and life sciences stakeholders seeking a clear understanding of the antiemetic drugs landscape.

Conclusion

Antiemetic drugs remain a foundational component of modern supportive care, enabling patients to continue cancer therapy, recover more efficiently after surgery, avoid preventable complications, and maintain nutrition, hydration, and quality of life. The industry is evolving from broad symptom control toward personalized prevention, evidence-based combination regimens, safety-led differentiation, and formulations suited to outpatient care. Regional dynamics vary widely, with mature markets emphasizing guideline adherence and value-based outcomes, while emerging markets prioritize access, affordability, infrastructure expansion, and supply continuity. Artificial intelligence adds a new layer of opportunity by improving risk prediction, real-world evidence generation, pharmacovigilance, and patient monitoring, provided that implementation is clinically validated and ethically governed. For industry leaders, the strongest opportunities lie in therapies and strategies that address delayed nausea, improve adherence, reduce care disruption, and integrate seamlessly into oncology, surgical, emergency, and primary care pathways. Sustained success will require balancing innovation with affordability, safety with convenience, and global strategy with local access realities.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Antiemetic Drugs Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Corticosteroids
  • 7.3. Dopamine Antagonists
  • 7.4. Neurokinin 1 Receptor Antagonists
  • 7.5. Serotonin 5-HT3 Receptor Antagonists

8. Antiemetic Drugs Market, by Indication

  • 8.1. Introduction
  • 8.2. Chemotherapy-Induced Nausea And Vomiting
  • 8.3. Post-Operative Nausea And Vomiting
  • 8.4. Radiation-Induced Nausea And Vomiting

9. Antiemetic Drugs Market, by Route Of Administration

  • 9.1. Introduction
  • 9.2. Intravenous
  • 9.3. Oral

10. Antiemetic Drugs Market, by End User

  • 10.1. Introduction
  • 10.2. Clinics
  • 10.3. Home Care Settings
  • 10.4. Hospitals

11. Antiemetic Drugs Market, by Molecule Type

  • 11.1. Introduction
  • 11.2. Small Molecule Drugs
  • 11.3. Biologic Drugs
  • 11.4. Cannabinoid Based Drugs

12. Antiemetic Drugs Market, by Distribution Channel

  • 12.1. Introduction
  • 12.2. Offline
  • 12.3. Online

13. Antiemetic Drugs Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. Europe
  • 13.3. North America
  • 13.4. Latin America
  • 13.5. Africa
  • 13.6. Middle East

14. Antiemetic Drugs Market, by Group

  • 14.1. NATO
  • 14.2. G7
  • 14.3. BRICS
  • 14.4. European Union
  • 14.5. ASEAN
  • 14.6. GCC

15. Antiemetic Drugs Market, by Country

  • 15.1. China
  • 15.2. United States
  • 15.3. Japan
  • 15.4. India
  • 15.5. Germany
  • 15.6. United Kingdom
  • 15.7. Australia
  • 15.8. France
  • 15.9. South Korea
  • 15.10. Italy
  • 15.11. Canada
  • 15.12. Russia
  • 15.13. Brazil
  • 15.14. Mexico
  • 15.15. Spain

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2025
  • 16.2. FPNV Positioning Matrix, 2025
  • 16.3. Market Concentration Analysis, 2025
    • 16.3.1. Concentration Ratio (CR)
    • 16.3.2. Herfindahl Hirschman Index (HHI)
  • 16.4. Recent Developments & Impact Analysis, 2025
  • 16.5. Product Portfolio Analysis, 2025
  • 16.6. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Abbott Laboratories
  • 17.2. Alkem Laboratories Limited
  • 17.3. Amgen Inc
  • 17.4. Astellas Pharma Inc
  • 17.5. AstraZeneca PLC
  • 17.6. Aurobindo Pharma Limited
  • 17.7. Baxter International Inc
  • 17.8. Boehringer Ingelheim International GmbH
  • 17.9. Cipla Limited
  • 17.10. Dr Reddys Laboratories Limited
  • 17.11. Eagle Pharmaceuticals Inc
  • 17.12. Eisai Co Ltd
  • 17.13. Eli Lilly and Company
  • 17.14. F Hoffmann-La Roche Ltd
  • 17.15. Fresenius Kabi AG
  • 17.16. Glenmark Pharmaceuticals Limited
  • 17.17. GSK plc
  • 17.18. Hikma Pharmaceuticals PLC
  • 17.19. Johnson & Johnson
  • 17.20. Lupin Limited
  • 17.21. Merck & Co Inc
  • 17.22. Novartis AG
  • 17.23. Pfizer Inc
  • 17.24. Sun Pharmaceutical Industries Limited
  • 17.25. Takeda Pharmaceutical Company Limited
  • 17.26. Teva Pharmaceutical Industries Limited
  • 17.27. Torrent Pharmaceuticals Limited
  • 17.28. Viatris Inc
  • 17.29. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIEMETIC DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL ANTIEMETIC DRUGS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL ANTIEMETIC DRUGS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL ANTIEMETIC DRUGS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL ANTIEMETIC DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 25. GLOBAL ANTIEMETIC DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL ANTIEMETIC DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DOPAMINE ANTAGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DOPAMINE ANTAGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DOPAMINE ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NEUROKININ 1 RECEPTOR ANTAGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEUROKININ 1 RECEPTOR ANTAGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NEUROKININ 1 RECEPTOR ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL POST-OPERATIVE NAUSEA AND VOMITING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL POST-OPERATIVE NAUSEA AND VOMITING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL POST-OPERATIVE NAUSEA AND VOMITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL RADIATION-INDUCED NAUSEA AND VOMITING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL RADIATION-INDUCED NAUSEA AND VOMITING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL RADIATION-INDUCED NAUSEA AND VOMITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SMALL MOLECULE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SMALL MOLECULE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SMALL MOLECULE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIOLOGIC DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BIOLOGIC DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIOLOGIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CANNABINOID BASED DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANNABINOID BASED DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CANNABINOID BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC ANTIEMETIC DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE ANTIEMETIC DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST ANTIEMETIC DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. NATO ANTIEMETIC DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. NATO ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 106. NATO ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 107. NATO ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 108. NATO ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. NATO ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. NATO ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. G7 ANTIEMETIC DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. G7 ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 113. G7 ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 114. G7 ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. G7 ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. G7 ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. G7 ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. BRICS ANTIEMETIC DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. BRICS ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 120. BRICS ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 121. BRICS ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 122. BRICS ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. BRICS ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION ANTIEMETIC DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPEAN UNION ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPEAN UNION ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN ANTIEMETIC DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. GCC ANTIEMETIC DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GCC ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 141. GCC ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 142. GCC ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 143. GCC ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. GCC ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. GCC ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. CHINA ANTIEMETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 148. CHINA ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 149. CHINA ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 150. CHINA ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 151. CHINA ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. CHINA ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. CHINA ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES ANTIEMETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 158. UNITED STATES ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. UNITED STATES ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. JAPAN ANTIEMETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 162. JAPAN ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 163. JAPAN ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 164. JAPAN ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 165. JAPAN ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. JAPAN ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. JAPAN ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 168. INDIA ANTIEMETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 169. INDIA ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 170. INDIA ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 171. INDIA ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 172. INDIA ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. INDIA ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. INDIA ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 175. GERMANY ANTIEMETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 176. GERMANY ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 177. GERMANY ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 178. GERMANY ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 179. GERMANY ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. GERMANY ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. GERMANY ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED KINGDOM ANTIEMETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED KINGDOM ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED KINGDOM ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED KINGDOM ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED KINGDOM ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED KINGDOM ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED KINGDOM ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. AUSTRALIA ANTIEMETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 190. AUSTRALIA ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 191. AUSTRALIA ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 192. AUSTRALIA ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 193. AUSTRALIA ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. AUSTRALIA ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. AUSTRALIA ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 196. FRANCE ANTIEMETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. FRANCE ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 198. FRANCE ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 199. FRANCE ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 200. FRANCE ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. FRANCE ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. FRANCE ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 203. SOUTH KOREA ANTIEMETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 204. SOUTH KOREA ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 205. SOUTH KOREA ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 206. SOUTH KOREA ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 207. SOUTH KOREA ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. SOUTH KOREA ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. SOUTH KOREA ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. ITALY ANTIEMETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 211. ITALY ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 212. ITALY ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 213. ITALY ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 214. ITALY ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. ITALY ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. ITALY ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 217. CANADA ANTIEMETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. CANADA ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 219. CANADA ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 220. CANADA ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 221. CANADA ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. CANADA ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. CANADA ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 224. RUSSIA ANTIEMETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 225. RUSSIA ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 226. RUSSIA ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 227. RUSSIA ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 228. RUSSIA ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. RUSSIA ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. RUSSIA ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 231. BRAZIL ANTIEMETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 232. BRAZIL ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 233. BRAZIL ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 234. BRAZIL ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 235. BRAZIL ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. BRAZIL ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. BRAZIL ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 238. MEXICO ANTIEMETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 239. MEXICO ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 240. MEXICO ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 241. MEXICO ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 242. MEXICO ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. MEXICO ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. MEXICO ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 245. SPAIN ANTIEMETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 246. SPAIN ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 247. SPAIN ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 248. SPAIN ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 249. SPAIN ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 250. SPAIN ANTIEMETIC DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. SPAIN ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 252. GLOBAL ANTIEMETIC DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • TABLE 253. GLOBAL ANTIEMETIC DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025